- Molecular NameDoxacurium
- SynonymNA
- Weight1106.14
- Drugbank_IDDB01334
- ACS_NO106819-53-8
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)N/A
- pkaN/A
- LogD (pH=7, predicted)N/A
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)N/A
- LogSw (predicted, AB/LogsW2.0)N/A
- Sw (mg/ml) (predicted, ACD/Labs)N/A
- No.of HBond DonorsN/A
- No.of HBond AcceptorsN/A
- No.of Rotatable BondsN/A
- TPSAN/A
- StatusFDA approved
- AdministrationN/A
- PharmacologyA muscle relaxant in the quaternary ammonium compound family.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- BioavailabilityN/A
- Protein binding31.0
- Volume of distribution (VD)0.23 (0.12 to 0.29) L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIt is not metabolised by plasma cholinesterase or hepatic enzymes.
- Half life1.7~2 h (healthy individuals); 3.7 h (patients with renal insufficiency).
- ExcretionDoxacurium is excreted in urine and bile, mostly as the unchanged parent drug. The drug is rapidly cleared from the body and is eliminated mainly in urine (70%) and also via bile. In healthy individuals, 24 to 38% of a dose is recovered unchanged in urine within 6 to 12 h after administration.
- Urinary ExcretionN/A
- Clerance2.5 ml/kg/min
- ToxicityOverdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.
- LD50 (rat)N/A
- LD50 (mouse)N/A